AIM ImmunoTech Inc. (NYSE:AIM - Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as $14.93 and last traded at $9.90, with a volume of 41869 shares. The stock had previously closed at $9.50.
AIM ImmunoTech Price Performance
The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75. The stock's 50 day simple moving average is $9.13 and its two-hundred day simple moving average is $14.16. The stock has a market cap of $665.79 million, a price-to-earnings ratio of -19.60 and a beta of 0.76.
AIM ImmunoTech Company Profile
(
Get Free Report)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Further Reading
Before you consider AIM ImmunoTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AIM ImmunoTech wasn't on the list.
While AIM ImmunoTech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
